A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
Premier submitted comments cautioning the DEA to carefully consider how a reduction in manufacturing quotas for certain opioids could rekindle recent drug shortages for injectable opioids and have a negative effect on patients with a legitimate and serious need for these medications. DEA proposes to reduce the aggregate production quotas (APQs) for several schedule II controlled substances in 2020 including:
These medications are critical to control pain during surgeries, interventional procedures, traumas, burns and other procedures where treatment with alternative pain therapies may not be.
In the comments, Premier urged the DEA to differentiate between solid oral dosage forms and injectables and ensure that quotas for injectable opioids are not impacted by the proposed reduction in APQs. Premier further urged the DEA to develop a process for temporarily reallocating quotas for injectable opioids to able and operational manufacturers to help alleviate ongoing and future potential shortages of injectable opioids.
Contact: Public_Relations@premierinc.com